| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 5mg | ¥900.00 | 现货 | 1 | |
| 10mg | ¥1,620.00 | 现货 | 1 | |
| 25mg | ¥2,880.00 | 现货 | 1 | |
| 50mg | ¥4,320.00 | 现货 | 1 | |
| 10mM (in 1mL DMSO) | ¥1,188.00 | 现货 | 1 |
Revefenacin (TD-4208, GSK-1160724) is a potent, lung-selective, long-acting muscarinic antagonist that may be for the treatment of respiratory disease.
Revefenacin is a high affinity competitive antagonist at human recombinant mAChRs with kinetic functional selectivity for M3 over M2 mAChRs and a potent, slowly reversible antagonist in rat, guinea pig, and human airway tissues expressing native mAChRs[1].
[1] Hegde SS, et al. Pharmacol Res Perspect. 2018, 6(3):e00400.
|
Animal experiment: |
Rats: To determine the bronchoprotective and antisialagogue potency after a single dose, rats are exposed by inhalation to a nebulized solution of revefenacin (3–3000 µg/mL), tiotropium (0.3–300 µg/mL), glycopyrronium (1–1000 µg/mL), or vehicle (sterile water). Bronchoprotective activity is assessed 24 hours postdose. For the antisialagogue effect, inhibition of Pilo is assessed 1, 6, or 12 hours after inhalation of an efficacious dose of test compound to determine the time point at which peak effect occurred. All subsequent doses are measured at this time point[2]. |
|
References: [1]. Steinfeld T, et al. In vitro characterization of TD-4208, a lung-selective and long-acting muscarinic antagonist bronchodilator (Abstract). Am J Respir Crit Care Med 179:A4553. |
